SG11202105326WA - Recombinant viral vectors and nucleic acids for producing the same - Google Patents
Recombinant viral vectors and nucleic acids for producing the sameInfo
- Publication number
- SG11202105326WA SG11202105326WA SG11202105326WA SG11202105326WA SG11202105326WA SG 11202105326W A SG11202105326W A SG 11202105326WA SG 11202105326W A SG11202105326W A SG 11202105326WA SG 11202105326W A SG11202105326W A SG 11202105326WA SG 11202105326W A SG11202105326W A SG 11202105326WA
- Authority
- SG
- Singapore
- Prior art keywords
- producing
- same
- nucleic acids
- viral vectors
- recombinant viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770202P | 2018-11-21 | 2018-11-21 | |
| PCT/US2019/062531 WO2020106916A1 (en) | 2018-11-21 | 2019-11-21 | Recombinant viral vectors and nucleic acids for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105326WA true SG11202105326WA (en) | 2021-06-29 |
Family
ID=70773595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105326WA SG11202105326WA (en) | 2018-11-21 | 2019-11-21 | Recombinant viral vectors and nucleic acids for producing the same |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210324418A1 (en) |
| EP (1) | EP3883954A4 (en) |
| JP (1) | JP2022508182A (en) |
| KR (1) | KR20210103469A (en) |
| CN (1) | CN113302201A (en) |
| AR (1) | AR117145A1 (en) |
| AU (1) | AU2019385506A1 (en) |
| BR (1) | BR112021009733A2 (en) |
| CA (1) | CA3120289A1 (en) |
| CL (1) | CL2021001327A1 (en) |
| CO (1) | CO2021008120A2 (en) |
| EA (1) | EA202191418A1 (en) |
| EC (1) | ECSP21044840A (en) |
| IL (1) | IL283344A (en) |
| MX (1) | MX2021005997A (en) |
| PE (1) | PE20211419A1 (en) |
| PH (1) | PH12021551155A1 (en) |
| SG (1) | SG11202105326WA (en) |
| TW (1) | TW202039533A (en) |
| WO (1) | WO2020106916A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107686842A (en) * | 2016-08-03 | 2018-02-13 | 南京大学 | A kind of target polynucleotide edit methods and its application |
| US11905523B2 (en) | 2019-10-17 | 2024-02-20 | Ginkgo Bioworks, Inc. | Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C |
| US20220010332A1 (en) * | 2020-07-08 | 2022-01-13 | Neuracle Genetics Inc. | Intron fragments |
| US20230285596A1 (en) * | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| EP4221761A1 (en) * | 2020-09-29 | 2023-08-09 | Neuexcell Therapeutics Inc. | Neurod1 combination vector |
| JP2023544068A (en) * | 2020-09-29 | 2023-10-19 | ニューエクセル・セラピューティクス・インコーポレイテッド | NEUROD1 vector |
| US20220098617A1 (en) * | 2020-09-29 | 2022-03-31 | NeuExcell Therapeutics Inc. | Ascl1 vector |
| WO2023221942A1 (en) * | 2022-05-16 | 2023-11-23 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant aav vectors for treating glutaric aciduria type i |
| WO2023240162A1 (en) * | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2024074143A1 (en) * | 2022-10-08 | 2024-04-11 | Lingyi Biotech Co., Ltd. | Construct for enhancing gene expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090221620A1 (en) * | 2008-02-20 | 2009-09-03 | Celera Corporation | Gentic polymorphisms associated with stroke, methods of detection and uses thereof |
| WO2015044704A1 (en) * | 2013-09-30 | 2015-04-02 | Sanofi | Use of neuroglobin agonist for preventing or treating mitochondrial rcci and/or rcciii deficiency disease |
| EP3632923A1 (en) * | 2015-01-16 | 2020-04-08 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
| US11040113B2 (en) * | 2015-03-23 | 2021-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia |
| PT3298134T (en) * | 2015-05-16 | 2023-08-18 | Genzyme Corp | Gene editing of deep intronic mutations |
| MX2018005084A (en) * | 2015-11-05 | 2019-05-16 | Bamboo Therapeutics Inc | Modified friedreich ataxia genes and vectors for gene therapy. |
| EP3390644A1 (en) * | 2015-12-15 | 2018-10-24 | Genzyme Corporation | Adeno-associated viral vectors for treating mucolipidosis type ii |
| US20210254056A1 (en) * | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
-
2019
- 2019-11-21 KR KR1020217017068A patent/KR20210103469A/en unknown
- 2019-11-21 CA CA3120289A patent/CA3120289A1/en active Pending
- 2019-11-21 EA EA202191418A patent/EA202191418A1/en unknown
- 2019-11-21 TW TW108142416A patent/TW202039533A/en unknown
- 2019-11-21 PE PE2021000747A patent/PE20211419A1/en unknown
- 2019-11-21 AU AU2019385506A patent/AU2019385506A1/en active Pending
- 2019-11-21 EP EP19887003.2A patent/EP3883954A4/en active Pending
- 2019-11-21 CN CN201980088932.7A patent/CN113302201A/en active Pending
- 2019-11-21 AR ARP190103423A patent/AR117145A1/en unknown
- 2019-11-21 WO PCT/US2019/062531 patent/WO2020106916A1/en unknown
- 2019-11-21 MX MX2021005997A patent/MX2021005997A/en unknown
- 2019-11-21 JP JP2021529002A patent/JP2022508182A/en active Pending
- 2019-11-21 SG SG11202105326WA patent/SG11202105326WA/en unknown
- 2019-11-21 BR BR112021009733A patent/BR112021009733A2/en unknown
-
2021
- 2021-05-20 PH PH12021551155A patent/PH12021551155A1/en unknown
- 2021-05-20 CL CL2021001327A patent/CL2021001327A1/en unknown
- 2021-05-20 IL IL283344A patent/IL283344A/en unknown
- 2021-05-21 US US17/326,884 patent/US20210324418A1/en active Pending
- 2021-06-21 CO CONC2021/0008120A patent/CO2021008120A2/en unknown
- 2021-06-21 EC ECSENADI202144840A patent/ECSP21044840A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022508182A (en) | 2022-01-19 |
| TW202039533A (en) | 2020-11-01 |
| AR117145A1 (en) | 2021-07-14 |
| ECSP21044840A (en) | 2021-09-30 |
| EP3883954A4 (en) | 2022-08-10 |
| PH12021551155A1 (en) | 2021-11-03 |
| KR20210103469A (en) | 2021-08-23 |
| EA202191418A1 (en) | 2021-08-05 |
| CA3120289A1 (en) | 2020-05-28 |
| US20210324418A1 (en) | 2021-10-21 |
| CL2021001327A1 (en) | 2021-12-31 |
| BR112021009733A2 (en) | 2022-01-04 |
| EP3883954A1 (en) | 2021-09-29 |
| CO2021008120A2 (en) | 2021-08-09 |
| WO2020106916A1 (en) | 2020-05-28 |
| MX2021005997A (en) | 2021-08-11 |
| IL283344A (en) | 2021-07-29 |
| PE20211419A1 (en) | 2021-08-03 |
| AU2019385506A1 (en) | 2021-06-03 |
| CN113302201A (en) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283344A (en) | Recombinant viral vectors and nucleic acids for producing the same | |
| SG10202110491PA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| IL282885A (en) | Aav viral vectors and uses thereof | |
| IL271993A (en) | Oncolytic viral vectors and uses thereof | |
| EP3325633A4 (en) | Recombinant vectors comprising 2a peptide | |
| EP3436576A4 (en) | Cell line for recombinant protein and/or viral vector production | |
| IL277666A (en) | Antibody-evading virus vectors | |
| SG11202009009UA (en) | Viral and non-viral nanoplasmid vectors with improved production | |
| IL264364B (en) | Humanized fc-gamma receptor proteins and nucleic acids encoding the same | |
| GB201814590D0 (en) | Viral vector production system | |
| IL286475A (en) | Methods for the manufacture of recombinant viral vectors | |
| ZA202100859B (en) | Recombinant protein variants | |
| IL277664A (en) | Antibody-evading virus vectors | |
| WO2015134332A3 (en) | Recombinant isfahan viral vectors | |
| ZA202100242B (en) | Recombinant nucleic acid construct | |
| IL288419A (en) | Recombinant herpesvirales vector | |
| PL3313864T3 (en) | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof | |
| EP3743084A4 (en) | Recombinant viral vaccines | |
| ZA202104244B (en) | Recombinant viruses and the uses thereof | |
| ZA202108996B (en) | Viral vector | |
| ZA202101433B (en) | An improved process for the preparation of recombinant lectin protein | |
| IL277128A (en) | Hepatitis b vaccines and uses of the same | |
| WO2016160976A3 (en) | Monovalent tnf binding proteins | |
| IL285983A (en) | Vectors and expression systems for producing recombinant proteins | |
| IL290715A (en) | Nkg2d fusion proteins and uses thereof |